Leishmania donovani, a protozoan parasite, causes the disease visceral leishmanisis (VL), characterized by inappropriate CD8 + T-cell activation. Therefore, we examined whether the 
Introduction
Visceral leishmaniasis caused by the protozoan parasite, Leishmania donovani, is fatal, if untreated. Dysfunctions of macrophages and T-cells during VL result in severe immunosuppression [1] [2] [3] . CD4
+ T-cells activation is essential for IFN-γ-mediated protection against leishmaniais [4] whereas CD8 + T-cells confer protection via perforin, granzyme-B-mediated direct killing of Leishmania-infected host cells [5] [6] . L. donovani induces functional exhaustion of CD8 + T-cells [7] . Activation of Leishmania-specific CD8 + T-cells is indispensable for clearance of the pathogen. For naive CD8 + T cells' antigen-specific activation and differentiation, signals from T-cell receptor, CD28, IL-12-induced IFN-γ and TLR2 are reqiured [8] [9] [10] [11] [12] . The transcription factor T-bet promotes naive CD8 + T-cell differentiation to effector cytotoxic T lymphocytes (CTL) [13] [14] , expressing CD25 (IL-2R-α), IL-12 receptor (IL-12R) and IFN-γR. TLR2, forming heterotypic associations with TLR1 or TLR6, recognizes triacetylated or diacetylated lipopeptides, respectively [15] [16] [17] . Ara-LAM, a cell wall glycolipid of Mycobacterium smegmatis, has been reported to confer protection against leishmanial pathogenesis via TLR2-dependent induction of the proinflammatory responses [18] . Ara-LAM-induced activation of p38 MAPK signalling in Leishmania infected macrophages shifts their Th2 phenotype towards Th1 via chromatin modification at various proinflammatory cytokine gene loci [19] . However, it was unclear if Ara-LAM would modulate TLR2 signalling in CD8 + T-cells, which might play a potential role in the regression of leishmanial pathogenesis.
In this study, we have demonstrated that Ara-LAM drives the activation of CD8 + T-cells, which are CD25 + CD28 + IL-12R + IFN-γR + and specifically destroys the L. donovani-infected macrophages. Ara-LAM enhances T-bet expression in CD8 + T-cells via upregulation of NF-κB and p38MAPK in a TLR2-dependent pathway. T-bet ultimately enhances the expression of IFN-γ, perforin, and granzyme-B in CD8 + T-cells via histone modifications at their respective promoter regions to restore host-protective CD8 + T-cell responses.
Materials and Methods

Reagents and chemicals
RPMI-1640 medium, penicillin and streptomycin, SB203580 (p38MAP Kinase inhibitor), SN50 (NF-κB inhibitor) were from Sigma (St. Louis, MO, USA). dNTPs, Revert Aid M-MuLV Reverse Transcriptase, oligo dT, RNase inhibitor and others for cDNA synthesis were from Fermentas (Ontario, Canada). Phospho-H3 and acetyl-H3 Abs were from Abcam (Cambridge, UK) and chromatin immunoprecipitation (ChIP) assay kit was from Millipore (Bedford, MA). TLR2, MyD88, IRAK 1, NF-κB, p38, phospho-p38, ERK1/2, phospho-ERK1/2, T-bet, β-Actin antibodies were from Santa Cruz Biotechnology (Texas, USA). Ara-LAM was isolated as previously described [20] . Lipopolysaccharide contamination (<25 ng/mg) was checked by the Limulus test. All antibodies for FACS were from BD Biosciences (San Diego, USA).
Animals and parasites
L. donovani strain AG-83 (MHOM/IN/1983/AG-83) was maintained in vitro in Medium-199 (Sigma, St. Louis, MO) with 10% FCS (Gibco-BRL) and virulence was maintained by passage through BALB/c mice. Stationary-phase promastigotes obtained by suitable transformation were used for experiments [21] . BALB/c mice were infected with stationary phase L. donovani promastigotes (i.v., 2×10 7 /mouse). BALB/c mice (6-8 weeks, NCLAS, Hydrabad, India) were divided into the following experimental groups: (1) control (receiving PBS); (2) infected (receiving L. donovani); (3) Infected and Ara-LAM-treated infected (Ara-LAM 30μg/kg body weight-injected 2 days prior to infection); (4) control shRNA and (5) TLR2 shRNA (TLR2 shRNA or control shRNA [bearing scrambled sequence] treatment 72h before Ara-LAM treatment). Mice were sacrificed on 14 and 28 days after infection by cervical dislocation method as mentioned by Institutional Animal Ethical Committee (Bose Institute), bearing a registration number: 1796/PO/ERe/S/14/CPCSEA. This study followed the Institutional Animal Ethical Committee approval. L. donovani infection was expressed in Leishman-Donovan units.
Isolation and purification of macrophages and CD8 + T-cells
Thioglycolate-elicited (i.p., 4% w/v, 1.0 ml/mouse) macrophages from different experimental groups of BALB/c mice were infected with stationary phase Leishmania promastigotes at a ratio of 1:10 [22] . Splenic CD8 + T-cells (purity >99% as ascertained by FACS) from the indicated mice were isolated by positive selection using CD8 + IMag beads, according to the manufacturer's instructions (BD Biosciences). CD8 + T-cells were cultured in RPMI-1640 with platebound anti-CD3ε (5μg/mL) and CD28 (1μg/mL).
Preparation of TLR2 and T-bet-specific siRNA TLR2 and T-bet-specific siRNA were synthesized using the Silencer siRNA Construction kit (Ambion). Scrambled siRNA was synthesized with the similar GC content. Silencing primers are listed in the Table 1 .
Flow cytometry CD8 + T-cells from differently treated mice groups were stained with PE-labeled TLR2, IFN-γ, IFN-γR, IL-12R, CD28 or IL-10, APC-Cy7 labelled CD25, FITC-lebelled IFN-γ. For intracellular cytokine staining, brefeldin A (10μg/mL) was added 4h prior to harvest, fixed, and permeabilized (0.1% saponin) and stained with anti-IFN-γ-PE, anti-perforin-PE and anti-granzyme-B-PE antibodies. Cells were analyzed using a FACS Verse flow cytometer.
Isolation of RNA and Reverse Transcriptase polymerase chain reaction
Total RNA from purified CD8 + T-cells were extracted using TRI reagent using standard protocol [23] . The total RNA was reverse transcribed using Revert Aid M-MuLV reverse transcriptase (Fermentas). GAPDH was used as a loading control. Sequences of the PCR primers are given in the Table 1 . [24] .
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were conducted using the ChIP Assay kit following the manufacturers protocol. Purified CD8 + T-cells (1×10 6 ) from the indicated mice were co-cultured with autologous L. donovani-infected macrophages (1×10 5 ) for 45 min, paraformaldehyde(1%)-fixed for 10 min at 37°C and washed with ice-cold PBS containing 1mM PMSF, harvested and lysed in SDS lysis buffer. DNA was sheared by ultrasonication using a High Intensity Ultrasonic Processor (Hielscher, Teltow, Germany) for 3 × 10s pulses at 20% amplitude. Lysates were cleared by centrifugation and diluted in ChIP dilution buffer. Lysates were pre-cleared using protein A-agarose and a sample of "input DNA" was collected at this point. Protein-DNA complexes were immunoprecipitated with 5μg of antibodies (phospho H3, acetyl H3, T-bet) overnight at 4°C. Antibody-protein-DNA complexes were then captured using protein A-agarose for 1 h at 4°C. After washing beads with low and high salt, LiCl, and TE buffers, the protein/DNA complexes were eluted in buffer (1%SDS, 0.1M NaHCO 3 ). DNA was then extracted and precipitated. PCR was conducted using promoter specific primers ( Table 1) .
Preparation of nuclear and cytoplasmic extracts
The nuclear extracts were prepared from CD8 + T-cells as described previously [25] . Briefly, cells were resuspended in ice-cold hypotonic buffer [10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, and 0.5 mM DTT] for 10 min, homogenized and the nuclei were precipitated (3300×g, 5 min, 4°C). The supernatant was used as the cytoplasmic extract. The nuclear pellet was extracted in ice-cold nuclear extraction buffer [20mM HEPES (pH 7.9), 0.4M NaCl, 1.5mM MgCl 2 , 0.2mM EDTA, 25% glycerol, 0.5mM PMSF and 0.5mM DTT] for 30min (12,000×g for 30 min, 4°C). The supernatant was used as nuclear extract.
Preparation of cell lysate and immunoblot analysis
CD8 + T-cells were lysed using lysis buffer for isolation of protein [26] . Equal amounts of protein (30μg) were subjected to 10% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked overnight with 3%BSA in Tris-saline buffer (pH 7.5), and immunoblotting was performed to detect MyD88, IRAK 1, NF-κB, T-bet, β-Actin, GAPDH, and phosphorylated or total p38MAPK and ERK1/2, as described previously [27] .
Coimmunoprecipitation
In coimmunoprecipitation studies, the lysates of differently treated CD8 + T-cells were incubated with specific antibody (TLR2, MyD88). The complexes were captured with immobilized Protein A-agarose beads, washed, resolved by 10% SDS-PAGE and developed with antibodies to MyD88 and IRAK 1 to detect TLR2-MyD88, MyD88-IRAK 1 interactions [28] .
Statistical analysis
All experiments were performed in triplicate and a minimum of 4 mice was used per group. The data, represented as mean values ± SD, are from one experiment that was performed at least 3 times. One-way ANOVA test (using a statistical package, Instat3) was employed to assess the significance of the differences. p0.001 was considered significant.
Results
Ara-LAM upregulates IL-12R and IFN-γR in CD8 + T-Cells in L. donovani infection
We studied the effect of Ara-LAM on BALB/c mice-derived CD8 + T-cells in indicated groups.
Naïve CD8 + T cells proliferate in response to TCR and CD28 signals, but reqiure IFN-γ and IL-12 to develop effector functions [29] [30] . We investigated the status of CD28 on CD8 + T cells expressing CD25, receptor for IL-12 (IL-12R) and IFN-γ (IFN-γR) [31] [32] . 28 days after infection, compared to the splenic CD8 + T cells of untreated infected mice, Ara-LAM strongly induced the expression of IL-12R and a moderate induction of IFN-γR on splenic CD8 + T cells, co-expresseing CD25 (Fig 1A) . Activation of TLR2 in CD8 + T-cells is associated with their enhanced effecter functions [18] [19] . Therefore, we tested whether Ara-LAM, being a TLR2 ligand, could activate the CD8 + T-cells by upregulating the transcription of perforin and granzyme-B. We observed a significant enhancement in both perforin and granzyme-B expression in CD8 + T-cells isolated from Ara-LAM treated L. donovani infected mice compared to that of untreated infected mice (Fig 1B) .
Ara-LAM-induced CD8 + T-cells activation in L. donovani infection is TLR2-dependent
We examined the effect of Ara-LAM treatment on TLR2 surface expression in CD8 + T-cells from different groups of BALB/c mice. Ara-LAM treatment significantly augmented the expression of TLR2 in splenic CD8 + T-cells on 14 and 28days post infection (Fig 2A) . Because we observed significantly enhanced expressions of IFN-γ, perforin and granzyme-B in CD8 + T-cells isolated from Ara-LAM treated L. donovani infected mice compared to that of TLR2 Mediated CD8 + T-Cell Activation untreated infected mice (Fig 2A) , we tested if TLR2 silencing could abrogate these effector functions. TLR2 silencing abrogated the Ara-LAM induced generation of IFN-γ, perforin, granzyme-B molecules in CD8 + T-cells isolated from the infected mice (Fig 2A and 2B ).
It has been noted earlier that Leishmania infection of the susceptible host results in apoptosis of T-cells, leading to impairment of cell-mediated immunity [33] . Therefore, we investigated whether Ara-LAM could restore the impaired CD8 + T-cell proliferation in Leishmaniainfected mice. Ara-LAM treatment resulted in significant enhancement of splenic CD8 + T-cell proliferation compared to the splenic CD8 + T-cells from untreated infected mice. The Ara-LAM-induced CD8 + T-cell proliferation was significantly attenuated during TLR2 silencing condition (Fig 2C) . These results suggested that Ara-LAM stimulation leads to the enhanced effector function as well as the proliferation of CD8 + T-cells via TLR2 dependent pathway.
Ara-LAM triggers T-bet recruitment and histone modification at the IFN-γ, Perforin and Granzyme-B promoter regions in CD8 + T-cells
The expressions of IFN-γ, perforin and granzyme-B in CD8 + T cells is principally regulated at the level of transcription, which, in turn, is strictly dependent upon the favourable histone modifications at their respective promoter regions [19] . Therefore, we performed ChIP assays to investigate whether the Ara-LAM-mediated enhancement of IFN-γ, perforin and granzyme-B expression in CD8 + T-cells was due to chromatin modification at their respective promoter regions. We observed a significantly higher level of phosphorylated ( Fig 3A) and acetylated ( Fig 3B) histones at the promoter regions of IFN-γ, perforin, granzyme-B in the splenic CD8 + T-cells of Ara-LAM treated L. donovani infected BALB/c mice relative to the splenic CD8 + Tcell from untreated infected mice. These Ara-LAM mediated histone modifications at the IFN-γ, perforin and granzyme-B promoter regions in CD8 + T-cells were significantly attenuated in TLR2 silenced condition (Fig 3A and 3B) . Therefore, Ara-LAM induced transcription favourable histone modifications at the IFN-γ, perforin, and granzyme-B loci of CD8 + T-cells in a TLR2 dependent pathway. The effector functions of CD8 + T-cells are predominantly regulated by the transcription factor T-bet [34] . Therefore, we investigated the accumulaion of T-bet in the splenic CD8 + T-cells of different experimental mice groups. Immunoblot analysis showed that accmulation of T-bet was significantly higher in the splenic CD8 + T-cells of Ara-LAM treated L. donovani infected mice compared to that of the untreated infected mice (Fig 3C) . T-bet binding at the promoter regions of IFN-γ, perforin, granzyme-B is a crucial event for the optimal induction of these effectors molecules in CD8 + T-cells [13] . Therefore, we performed ChIP-on-ChIP assay to investigate the interaction of T-bet with the promoter regions of IFN-γ, perforin, and granzyme-B in CD8 + T-cells from Ara-LAM treated and untreated L. donovani infected BALB/c mice. Ara-LAM treatment induced a strong association of T-bet with the IFN-γ, perforin, and granzyme-B promoter regions in CD8 + T-cells compared with that of the untreated L. donovani infected mice; TLR2 silencing decreased Ara-LAM induced T-bet recruitment to the promoter regions of IFN-γ, perforin, granzyme-B in CD8 + T-cells (Fig 3D) . Collectively, Ara-LAM-induced TLR2 dependent activation of T-bet augmented the transcription of target effector genes in CD8 + T-cells of infected mice.
Ara-LAM promotes NF-κB activation and MAPK signaling in CD8 + Tcells
Ara-LAM triggers the TLR2 mediated downstream signaling in host macrophages [18] [19] . However, Ara-LAM induced modulation of TLR2 signaling in CD8 + T-cells has not been explored till date. The association between TLR2 and MyD88 is a crucial event for the initiation of TLR2 downstream signaling [18] . Therefore, we carried out co-immunoprecipitation studies to investigate the TLR2-MyD88 interaction in Ara-LAM-treated CD8 + T-cell. We observed a strong association between TLR2 and MyD88 in Ara-LAM-treated CD8 + T-cell compared with that of the untreated CD8 + T-cells. IRAK-1, crucial for activation of TLR2 downstream signaling [18] , was found to be intricately associated with MyD88 in Ara-LAM-treated CD8 + T-cells compared to the untreated CD8 + T-cells (Fig 4A) . Furthermore, nuclear translocation of NF-κB were significantly augmented in Ara-LAM treated CD8 + T-cell compared to the (Fig 4B) . In addition to the NF-κB activation, TLR2 signaling can also modulate p38 and ERK-1/2 MAPK signaling cascades [19] . Therefore, we investigated whether Ara-LAM treatment could induce MAPK phosphorylation in CD8 + T-cells. Ara-LAM treatment resulted in significantly higher level of p38MAPK phosphorylation ( Fig 4C) , however; it failed to induce significant ERK1/2 phosphorylation in CD8 + T-cells (Fig 4C) . TLR2 silencing abrogated the Ara-LAM induced p38 phosphorylation (Fig 4D) . Taken together, Ara-LAM activated p38MAPK and NF-κB activation in infected CD8 + T-cells. /mL) were stimulated with plate-bound anti-CD3ε mAbs (5μg/mL) and CD28 (1μg/mL) for 24 hrs and transfected with control siRNA or TLR2 siRNA, followed by Ara-LAM (3μg/mL) treatment for 24 hr. The cells were then lysed and subjected to immunoprecipitation with anti-TLR2 antibody, and the blots were probed with anti-MyD88 antibody. (B) Cells were lysed and immunoprecipitated with anti-MyD88 antibody; the blots were probed with anti-IRAK1 antibody. Cytosolic and nuclear protein extracts were analyzed for nuclear translocation of NF-κB. (C-D) In yet separate experiments, CD8 + T cells were treated by Ara-LAM for 5, 15, 30, and 60 min, and lysed. The lysate was subjected to Western blot analysis for the expression of p38MAPK, phospho-p38MAPK and ERK1/2, phospho-ERK1/2. Data represented were one of the three indepenedent experiments with similar results performed in the same way. doi:10.1371/journal.pone.0142800.g004
Ara-LAM enhances T-bet expression in CD8 + T-cells via upregulation of NF-κB and p38MAPK signaling Since, Ara-LAM induced efficient activation of T-bet in CD8 + T-cells (Fig 3C) and enhanced the activation of NF-κB and p38MAPK in CD8 + T-cell (Fig 4) , we hypothesized that T-bet activation in CD8 + T-cells might be regulated either by the NF-κB or MAPK signalling or by both of these signalling molecules. Ara-LAM mediated activation as well as mRNA expression of Tbet was attenuated in the presence of SB203580 and SN50, the pharmacological inhibitors of p38MAPK and NF-κB, respectively (Fig 5A and 5B) , suggesting that the activation of T-bet in Ara-LAM treated CD8 + T-cells was regulated by TLR2 triggered NF-κB and p38MAPK signalling cascade. Besides, the enhanced IFN-γ, perforin and granzyme-B expression in Ara-LAM stimulated CD8 + T-cells were significantly decreased during T-bet silencing, as well as, NF-κB and the p38MAPK inhibition (Fig 5B) . Therefore, the upregulation of IFN-γ, perforin and granzyme-B expression in Ara-LAM stimulated CD8 + T-cells were due to the NF-κB and the p38MAPK dependent activation of T-bet.
Ara-LAM reduces hepatic and splenic parasitic burden in BALB/c mice
We have observed that Ara-LAM activates the CD8 + T cells via upregulation of IFN-γ and the cytotoxic molecules perforin and granzyme-B. These activated T cells have the ability to kill the infected macrophages to reduce the parasite burden [5] [6] . In accordance with this phenomenon, we observed a significant reduction of the hepatic as well as splenic parasite burden in the Ara-LAM treated infected mice groups compared to the untreated infected mice groups (Fig 6) on 14 and 28days postinfection. However, Ara-LAM mediated clearance of parasites was significantly attenuated in TLR2 silenced condition. Collectively, the data clearly suggest that Ara-LAM plays a very important role to clear the L. donovani infection via a TLR2 dependent mechanism. + T-cells were isolated by MACS from the spleen BALB/c mice. Purified CD8 + T cells were stimulated as described previously and allowed to transfect with control siRNA or T-bet siRNA, or treated with SB203580 (SB) (5μg/ml), or SN50 (SN) (20μg/ml), subsequently followed by Ara-LAM (3μg/mL) treatment for 24 hr. The cells were then lysed and nuclear protein extracts were prepared, followed by subjected to Western blot with anti-T-bet. (B) The blot shown is representative of triplicate experiments that yield similar type of results. In a separate set of experiments, after the treatment schedule, the cells were collected in Trizol for RNA extraction, and conventional RT PCR analysis was performed to determine the expression of T-bet, IFN-γ, perforin, granzyme-B. Data represented were one of the three indepenedent experiments with similar results performed in the same way.
doi:10.1371/journal.pone.0142800.g005
Reversion of the Th subset expansion in L. donovani infected mice
We checked the effect of Ara-LAM on IFN-γ and IL-10 producing-CD8 + T-cells in both spleen and liver by flow cytometry. In both uninfected and infected mice, Ara-LAM up-regulated the IFN-γ secreting CD8 + T-cells in spleen as well as liver. IL-10 producing CD8 + T-cells were suppressed by Ara-LAM pretreatment in both spleen and liver of infected as well as uninfected mice. Although in case of hepatic CD8 + T-cells, the effect of Ara-LAM on both IFN-γ and IL-10 secretion was not very significant (Fig 7) .
Discussion
Leishmanial pathogenesis is associated with abrogated pro-inflammatory responses, resulting in immune suppression of the host [9] [10] [11] . The persistence of the infection during VL was due to the impaired cell-mediated immunity which in turn was intricately associated with the TLR2 Mediated CD8 + T-Cell Activation severe dysfunction of cytotoxic CD8 + T-cells [7] . Therefore, activation of CD8 + T cells is very much important to eradicate L. donovani mediated infection. Recently, it has been reported that activation of TLR signalling could restore the impaired effector function of CD8 + T-cells in various models of infectious diseases [35] . Therefore, we intended to study whether Ara-LAM, so far known to be a TLR2 ligand [18] , could restore the functional capacity of the effector CD8 + T-cells during VL.
We confirmed that Ara-LAM pre-treatment in L. donovani infected BALB/c mice significantly augmented the expression of TLR2 along with the concomitant increase in IFN-γ, perforin, and granzyme-B in the splenic CD8 + T-cells (Figs 1 and 2 ). Because knowing phenotype is important for its functional significance, we examined the phenotype of these T cells, which are IL-12R + IFN-γ + CD28 + co-expressing CD25 (Fig 1A) . Moreover, Ara-LAM pre-treatment was found to be associated with significant enhancement of CD8 + T-cell proliferation (Fig 2C) , a prerequisite for its effector function. TLR2 silencing significantly attenuated such Ara-LAM mediated enhanced expression of these effector molecules in CD8 + T-cells (Fig 2) .
The optimal transcriptional induction of the IFN-γ, perforin, granzyme-B genes in CD8 + Tcells requires histone modification at their respective promoter regions [19] . Our study revealed that Ara-LAM pretreatment led to transcription favourable histone H3 phosphorylation and acetylation specifically at the promoter region of IFN-γ, perforin, granzyme-B in the splenic CD8 + T-cells of L. donovani-infected BALB/c mice (Fig 3A and 3B ). In line with the fact that the activation of the transcription factor T-bet is a crucial event for the expression of IFN-γ, perforin, granzyme-B in CD8 + T-cells [13, 34] , we observed an increased T-bet accumulaion ( Fig 3C) along with enhanced T-bet binding to the promoter regions of IFN-γ, perforin, granzyme-B in the Ara-LAM treated splenic CD8 + T-cells of L. donovani infected BALB/c mice ( Fig 3D) . Hence, our study revealed that Ara-LAM induces T-bet dependent activation of effector molecules in CD8 + T-cells to hinder leishmanial pathogenesis. Further, we intended to investigate the underlying molecular mechanism of Ara-LAM induced CD8
+ T-cells activation during VL. Since, Ara-LAM confers its protective functions against VL via activation of the TLR2 downstream signaling in host macrophages [18] [19] , we investigated Ara-LAM mediated modulation of TLR2 signaling in CD8 + T-cells. Ara-LAM treatment led to successful initiation of TLR2 signalling in naive CD8 + T-cells via the TLR2-MyD88 association (Fig 4A) , resulting in the selective activation of intermediate signalling molecules, IRAK1 and ultimately leading to nuclear translocation of NF-κB (Fig 4B) . Ara-LAM treatment also led to increased p38MAPK phosphorylation along with concomitant attenuation of ERK1/2 phosphorylation in splenic CD8 + T-cells (Fig 4C and 4D) . These observations indicate that Ara-LAM induced activation of TLR2 downstream signalling molecules leads to enhanced effector function of CD8 + T-cells during VL.
We observed that inhibition of NF-κB and p38MAPK, by their respective pharmacological inhibitors, significantly abrogated the Ara-LAM-induced T-bet expression and activation in CD8 + T-cells (Fig 5A and 5B) . Our results indicated the active involvement of NF-κB and p38MAPK signalling in the regulation of Ara-LAM driven T-bet activation. Further, Ara-LAM treatment significantly reduced the parasite burden in the liver and spleen 14 and 28 days after the infection (Fig 6) accompanied with the expansion of IFN-γ + CD8 + T-cells (Fig 7) . It is therefore feasible to conclude that Ara-LAM mediated reduced parasitic burden may be due to the CD8 + T-cell driven killing of the infected macrophages. It is noteworthy to mention that Ara-LAM works well when utilized as an immunotherapiutic agent administered 2days prior to L. donovani infection [18] [19] [20] 28] . In summary, Ara-LAM confers significant protection through activation of CD8 + T-cells in L. donovani infected BALB/c mice. The novelty of our work lies in the fact that Ara-LAMinduced TLR2 signaling leads to the activation of the transcription factor T-bet which plays a pivotal role in restoring the effector functions of CD8 + T-cells in L. donovani infected susceptible host. Thus, we are one the way to devise a strategy in near future so that Ara-LAM can be used as a suitable vaccine during L. donovani infection.
